TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03573648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~* Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~* Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~* Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~* Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~* Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~* Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Palbociclib (125 mg) will be given orally on days 1-21 of each cycle x 4 cycles.
Study: NCT00966186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion fo ProSeal laryngeal mask airway
Description: Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion fo ProSeal laryngeal mask airway
Description: Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
Study: NCT04139330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-06
Description: Infuse NPC-06 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-06
Description: Infuse NPC-06 intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPC-06
Description: Infuse NPC-06 intravenously
Study: NCT01264341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.
Study: NCT01099696

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. infantis 35624
Description: B. infantis 35624 in white capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: white placebo capsules
Study: NCT01762696

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET
Description: Motivational Enhancement Therapy only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET
Description: Motivational Enhancement Therapy only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMENT
Description: The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
Study: NCT01885429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Positive Control
Description: Subject consumes 25g of whey protein following unilateral exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Negative Control
Description: Subject consumes 6.25g of whey protein following unilateral exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Protein Low Leucine Spike
Description: Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Protein High Leucine Spike
Description: Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Protein + High Leucine + BCAA Spike
Description: Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
Study: NCT02640274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led counselling programme
Description: The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Study: NCT03954639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 13.3Mg/mL Suspension for Injection
Description: Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 13.3Mg/mL Suspension for Injection
Description: Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Combined Sciatic and Adductor Canal Nerve Block with Bupivacaine HCL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Combined Sciatic and Adductor Canal Nerve Block with Bupivacaine HCL
Study: NCT02388243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention in Public Clinic
Description: The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing techniques, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a public clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Results in Public Clinic
Description: At each public clinic, a community health worker will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The community health worker will provide the results of the BMI, physical activity and the ASSIST and will offer a leaflet with further explanation about how to address problems with those lifestyles
Study: NCT00790803

Intervention type: DRUG
Group type: OTHER
Intervention: Pegaptanib
Description: Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
Study: NCT02157818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT04244448

Intervention type: DRUG
Group type: OTHER
Intervention: receive dissolved form of BIKTARVY®
Description: The healthy volunteers will receive dissolved form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).

Intervention type: DRUG
Group type: OTHER
Intervention: receive crushed form of BIKTARVY®
Description: The healthy volunteers will receive crushed form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).

Intervention type: DRUG
Group type: OTHER
Intervention: receive solid form of BIKTARVY®
Description: The healthy volunteers will receive solid form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
Study: NCT03165617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIVc
Description: Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-influenza Comparator Vaccine
Description: Non-influenza comparator vaccine for intramuscular use
Study: NCT02443467

Intervention type: OTHER
Intervention: No intervention
Study: NCT03359538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
Study: NCT00005975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate 20mg/day
Description: Double blinded Megestrol Acetate 20 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate 40 mg/day
Description: Double blinded Megestrol Acetate 40 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate Placebo 20 mg/day
Description: Megestrol Acetate Placebo 20 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate Placebo 40 mg/day
Description: Megestrol Acetate Placebo 40 mg/day
Study: NCT01480154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study: NCT04056819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells
Description: UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.
Study: NCT04430920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive intraoperative blood pressure management
Description: Targeting intraoperative mean arterial pressure ≥ 80 mmHg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional intraoperative blood pressure management
Description: Targeting intraoperative mean arterial pressure ≥ 65 mmHg or 60% of the baseline level (use the higher target).
Study: NCT02388243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention in Private Clinic
Description: The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing technics, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a private clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Results in Private Clinic
Description: At each private clinic, a support staff will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The support staff will provide the results of the BMI, physical activity and the ASSIST, and will offer a leaflet with further explanation about how to address problems with those lifestyles.
Study: NCT04572308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T
Description: Patients will be treated with CD7 CAR-T cells~Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
Study: NCT01153958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colposeptine
Description: Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
Study: NCT04283669

Intervention type: DRUG
Group type: OTHER
Intervention: Crizotinib
Description: Oral
Study: NCT01153958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
Study: NCT03299972

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: 25 g whey protein supplementation twice daily (breakfast and lunch)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: 25 g whey protein supplementation twice daily (breakfast and lunch)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 23.75 g maltodextrin twice daily (breakfast and lunch)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: 23.75 g maltodextrin twice daily (breakfast and lunch)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minutes of resistance exercise twice a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minutes of resistance exercise twice a week
Study: NCT02670759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of bupivacaine
Description: The infusion of local anesthetics will be initiated using a conventional infusion pump and will be transferred on a portable elastomeric pump before discharge from the hospital if the patient is discharged the day after surgery or at the latest on the second morning following surgery. The infusion will continue on the portable pump for 30 hours.
Study: NCT03237624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Chitosan Chewing Gum
Description: Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Chewing Gum
Description: Control chewing gum device does not have food additive chitosan in its composition.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral hygiene measures
Description: Patients will be given instructions on how to brush and floss routinely (twice per day)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene measures
Description: Patients will be given instructions on how to brush and floss routinely (twice per day)
Study: NCT04133883

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound, Haemophilia Joint Health Score
Description: Systematic joint examinations of ankles, knees and elbows
Study: NCT04506437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based mental health navigation
Description: Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based mental health navigation
Description: Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
Study: NCT02670759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single dose of bupivacaine
Description: A single dose of bupivacaine will be administered at the end of surgery before skin closure.
Study: NCT02341027

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jadelle
Description: within 5 days of delivery and before discharge from hospital
Study: NCT04506437

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care engagement practices
Description: Standard of care engagement practices and services-as-usual
Study: NCT04819126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Virtual Reality Application
Description: The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes.
Study: NCT02004236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tRNS Fronto-temporal cortex
Description: This group receive 35 sessions of tRNS over fronto-temporal cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tRNS over fusiform temporal cortex
Description: This group receive 35 sessions of tRNS over fusiform temporal cortex

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tRNS with sham
Description: the subjects receive 35 session with sham
Study: NCT02400216

Intervention type: DRUG
Intervention: dual cholate
Description: test for defining disease severity

Intervention type: DRUG
Intervention: dual cholate
Description: test for defining disease severity
Study: NCT05622630

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-cell bath
Description: Four-cell bath:Treatment with direct current

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gravel bath
Description: Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
Study: NCT00773448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comprehensive computed tomography of the abdomen/pelvis
Description: Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited Malignancy Screening
Description: 1) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)~In women, a pap smear/pelvic examination (if \> 18 and \< 70 years old and not performed during the past year),a mammogram (\> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (\>40 years old) will be performed if not conducted in the past year.
Study: NCT03113851

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: One lesion received radiotherapy for 35 Gy in 10 fractions and rested for one week; then another metastatic lesion were treated with radiotherapy for 35 Gy in 10 fractions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
Study: NCT00802581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumferential spread of local anesthetic
Description: The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-circumferential spread of local anesthetic
Description: The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve.
Study: NCT02325934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stribild
Description: Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild, crushed
Description: Crushed Stribild tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild, crushed
Description: Crushed Stribild tablet
Study: NCT02341027

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jadelle
Description: 6-8 weeks (42-56 days) postpartum
Study: NCT01780181

Intervention type: DRUG
Intervention: TCM
Description: TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.